Cystic Fibrosis

Edit Answers
12345678910111213141516171819202122232425262728293031323334353637383940414243444546
Across
  1. 1. The median age of diagnosis of Cystic Fibrosis is 6 to 8 _______
  2. 4. _______ is the preferred treatment for individuals with CFRD
  3. 5. Patients with CFRD may have falsely ___ hemoglobin A1c levels
  4. 6. Pulmonary ________ testing is used for evaluating and monitoring the progression of Cystic Fibrosis
  5. 7. Patients with Cystic Fibrosis should be ____________ at the sign of acute illness
  6. 12. The most common pulmonary function test is _________
  7. 13. ______________ complications are the most common complications in patients with CFRD
  8. 16. Patients with Cystic Fibrosis have thicker _____ secretions on epithelial linings
  9. 17. Gallbladder disease is common in patients with Cystic Fibrosis, with up to 15% having __________
  10. 20. The mutation that causes Cystic Fibrosis leads to premature destruction of the _____ apparatus
  11. 21. Mucus plugging in the ___________ results in obstructive lung disease
  12. 22. Cystic Fibrosis-related diabetes is believed to be ______________
  13. 23. ____________ is common in Type I Diabetes but not in CFRD
  14. 26. Patients with Cystic Fibrosis live to about the ______ decade of life before needing a lung transplant
  15. 28. The mutation that causes Cystic Fibrosis is found on Chromosome _____
  16. 31. Patients with CFRD may develop insulin ___________ leading to increased insulin requirements
  17. 32. _________ was the first CFTR modulator to become available for use in the United States
  18. 35. An increased risk factor for CFRD is premature loss of ________ function
  19. 36. Obstruction caused by mucus plugging creates an optimal environment for _________ growth
  20. 37. ____ modulator therapies are designed to correct dysfunction
  21. 38. Females with Cystic Fibrosis may be infertile due to thickened ________ mucus
  22. 39. Males with Cystic Fibrosis may be infertile due to ______ vas deferens
  23. 41. A pulmonary ____________ is the worsening of lung function due to infection
  24. 42. Pancreatic malfunction in patients with Cystic Fibrosis leads to Type I ________
  25. 44. Cystic Fibrosis is a _______ disease
  26. 45. Cystic Fibrosis is the most _____ genetic disorder among Caucasians
  27. 46. Cystic Fibrosis is caused by a ________
Down
  1. 2. _____ disease occurs in patients with Cystic Fibrosis because of an increase in secretion viscosity
  2. 3. The most common cause of death in Cystic Fibrosis patients is end-stage ____ disease
  3. 5. Lung transplantation does not cure Cystic Fibrosis, only offers a relief of symptoms and prolongs ____
  4. 8. A medication for Cystic Fibrosis patients that became available for use but only in combination with ivacaftor for patients who are homozygous for the Phe508del mutation is __________
  5. 9. Monitoring growth and ______ trends is crucial in pediatric patients with CFRD
  6. 10. __________ are vital for patients with CFRD for education and insulin management
  7. 11. The result of mutations is an increased resorption of ______
  8. 14. Patients with Cystic Fibrosis have high levels of ____ in their sweat
  9. 15. Cystic Fibrosis management involves clearing mucus in airways and controlling ___________ infection
  10. 18. Pancreatic manifestations in Cystic fibrosis patients are due to obstruction of pancreatic ________
  11. 19. Adult patients with Cystic Fibrosis are most likely to be _________
  12. 22. Intestinal involvement is most likely seen when the patient is born with ________ ileus
  13. 24. The result of mutations is a decreased secretion of ________
  14. 25. CFTR mutations result in abnormal beta-cell function with _________ insulin secretion
  15. 27. A defective CFTR protein causes structural damage to pancreatic _____ cells
  16. 28. Newborns are screened for Cystic Fibrosis as part of a ________ newborn screening panel
  17. 29. During trials for ivacaftor, there was a large occurrence of patients with increased serum ________________ levels
  18. 30. The third medication for Cystic Fibrosis patients to become available was __________
  19. 33. Cystic Fibrosis has no ____
  20. 34. he two primary goals for managing pulmonary illness are to treat the infection and improve ___________
  21. 40. Cystic Fibrosis patients have ______ lungs in utero, at birth, and after birth
  22. 43. The treatment for end-stage lung disease is lung ___________
  23. 45. Patients with Cystic Fibrosis are encouraged to consume a high ___ diet